Articles

Virtual R&D improves the certainty that drugs invested in will eventually make it to market, allowing pharmaceutical companies to reap back with investment on R&D. However, the move to virtual R&D will result in what PwC describes as a more "challenging and demanding landscape" in which third-party collaborative efforts on R&D will emerge as the norm. Read more

Signs suggest innovative business development and licensing strategies will continue to move from strength to strength as the industry adjusts to new dynamics and new business models. Read more

Cases of counterfeit pharmaceuticals being discovered entering the United States are on the up. Up 200 percent to $11 million (£7 million) in 2011 to be precise, based on the domestic value of seizures from the Customs and Border Protection (CBP) last year. Read more

In preparation for the Transport Packaging Summit 2012, taking place in June, I would like to invite you to take part in a short survey. The survey consists of no more than 9 questions and will take less than 5 minutes to complete. Read more

"This year I am excited to be attending the conference as the topics are current and the case studies, solutions discussed, and tools to use will be of tremendous value to myself and all the attendees," said Steve Jacobs, Chair of the Global Clinical Supplies Group. Read more

Today, there is a controversy about adequate quality of diabetes care and the best concept for the implementation of National Diabetes Plans. In September 2011 the United Nations Summit for Non Communicable Diseases agreed on a consensus that national plans for prevention and control of diabetes have to be developed, implemented and monitored. Read more

When looking at overall spending for 2011 and projected outsourcing spend for 2012, one can determine which customer segments to target based on how the services offered by providers compare to the needs of each segment. Big Pharma showed an increased need for bio-analytical testing, process optimization, stability storage and testing, cytotoxic projects and toxicology. Read more

It is clear some work has begun to increase the number of clinical trials in Norway, Sweden, Denmark, Finland and Iceland. Read more

According to a recent Pharma IQ survey, 43 per cent of Pharma professionals do not think the oversight of their clinical trial vendors is effective and 100 per cent claimed that the increasing levels of regulatory scrutiny are adding unnecessary pressure. Read more

Further drivers include decentralisation via personalised sequencing platforms that will make the technology available to individual laboratories and increased reagent usage on the current high throughput platforms installed base. Read more

What is the greatest challenge you face in the distribution and storage of controlled room temperature and ambient products? Understanding regulatory requirements? Finding cost-effective solutions? Take this short survey online, it will only take 2 minutes to complete. Read more